Allergan Aesthetics has revamped the Allergan Partner Privileges loyalty program, adjusting rebate tiers, volume incentives, and practice support offerings. The refresh reflects competitive pressure from Evolus (Jeuveau rebates), Galderma (Dysport/Restylane bundling), and direct-to-practice toxin suppliers.
Business & M&A
Allergan Refreshes Partner Privileges Loyalty Program
AbbVie updates rebate and incentive structure for Botox and filler practices.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |
Allergan updates rebate structure amid competitive pressure from Evolus and Galderma.
The specifics matter: practices should audit current rebate rates, volume thresholds, and any changes to exclusivity clauses or bundling requirements. AbbVie's move signals confidence in Botox's market position but also acknowledgment that loyalty cannot be assumed. Practices with mixed toxin portfolios should compare the new Allergan terms against Evolus Rewards and Galderma's incentive structures. The timing—mid-2026—suggests AbbVie is defending share ahead of potential new competitor launches and the Botox masseter indication approval.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.